NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/18/2024
Back to search
Official data from USPTO
IMMUNOVEDA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
14
Latest update
06/18/2024
Classification
Registered
Trademark type
Combined
Nice classes
42
Filing date
06/01/2023
Registration date
06/18/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/18/2024
Last transaction
06/18/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2020-11-00
First use in commerce
2020-11-00
Drawing code
3
Owner type
16
Owner location
Hamilton, NJ
Examiner
ALESKOW, DAVID HOWARD
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "IMMUNOVEDA" in purple, above the letter "I" is a purple dot; starting from this first dot is series of gradient purple to blue dots with each dot getting smaller in size and lighter in contrast to the first dot, and the space between the dots increases as the dots sweep upward in a curve toward the top of the mark, creating a band of dots, reaching an apex whereupon they descend in a curve toward the letter "A", upon reaching the letter "A" in one single dot whereupon they end. The color white represents background and transparent areas and is not part of the mark.
Holders and representatives
Holders
Genesis Drug, Discovery & Development, LLC
Representatives
Christina E. Brule Heslin Rothenberg Farley & Mesiti P.C.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Providing laboratory research services in the field of gene expressioncancer biology
Publications
History of USPTO decisions and trademark events.
14 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/18/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/02/2024
PUBO
PUBLISHED FOR OPPOSITION
04/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/13/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/23/2024
DOCK
ASSIGNED TO EXAMINER
02/23/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/15/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/15/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/15/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/15/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/07/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2023
NWAP
NEW APPLICATION ENTERED
06/05/2023
Continuous trademark protection
Get notified about every new filing that threatens IMMUNOVEDA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.